RTW Investments Portfolio
13F Holdings & Position Changes — Last filed Jun 30, 2026
13F Holdings & Position Changes — Last filed Jun 30, 2026
RTW had no new buys this quarter. Portfolio shrank -100.0% to $0.
Track this fund’s next move
13F changes, conviction shifts, and catalyst alerts across all 20 specialist biotech funds — free Monday brief.
RTW Investments's holdings this quarter are tracked from their SEC 13F filings. Visit their portfolio page on BiotechEdge for the full breakdown.
RTW Investments's tracked biotech portfolio is worth $0 across 0 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
RTW Investments did not initiate any new positions this quarter, but increased 0 existing holdings.
RTW Investments did not fully exit any positions this quarter.
Data-driven biotech fund led by a physician-investor who combines clinical expertise with quantitative analysis. RTW takes concentrated positions across the biotech lifecycle, from crossover privates to public equities, with a focus on therapeutic areas where clinical data can be independently modeled.